Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]) announced it has forged an alliance with Japan’s Kyowa Hakko Kogyo to commercialize the Cambridge, MA-based firm’s RNAi-based treatment for respiratory syncytial virus in Japan and other major Asian markets. The deal calls for Kyowa Hakko to pay Alnylam $15 million upfront, with as much as $78 million in development and sales milestone payments, plus royalties, on the table.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
